Evaluating PARP and ER Targeting in ER+/HER2

https://is1-ssl.mzstatic.com/image/thumb/Podcasts115/v4/32/43/8d/32438d12-f214-2b84-a090-4cb5c1fd55ff/mza_1588204697638323759.jpg/600x600bb.jpg

Project Oncology®

ReachMD

189 episodes

3 days ago

Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer. Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.

Science

Medicine

RSS

All content for Project Oncology® is the property of ReachMD and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Science

Medicine

Evaluating PARP and ER Targeting in ER+/HER2– Breast Cancer

Project Oncology®

7 minutes

2 weeks ago

Evaluating PARP and ER Targeting in ER+/HER2– Breast Cancer

Host: Pavani Chalasani, MD, MPH
Guest: Timothy Yap, MBBS, PhD, FRCP

Early findings from the PETRA study suggest that combining saruparib with camizestrant may offer added clinical benefit in ER+/HER2– advanced breast cancer, particularly in patients with BRCA or PALB2 mutations. Tune in to hear from Dr. Pavani Chalasani and Dr. Timothy Yap as they discuss this encouraging new data on tolerability and antitumor activity. Dr. Yap is the Ransom Horne, Jr. Endowed Professor for Cancer Research, Vice President and Head of Clinical Development in the Therapeutic Discovery Division, and a professor in the Department of Investigational Cancer Therapeutics at the University of Texas MD Anderson Cancer Center. He recently presented this research at the 2025 San Antonio Breast Cancer Symposium.